Portland, ORNCT06895473Now EnrollingIRB Ready

Hematopoietic and Lymphatic System Neoplasm Clinical Trial in Portland, OR

Access cutting-edge hematopoietic and lymphatic system neoplasm treatment through this phase 2 clinical trial at a research site in Portland. Study-provided care at no cost to qualified participants.

Sponsored by OHSU Knight Cancer Institute

Quick Self-Assessment

See if you qualify for this Portland location

Preparing your pre-screening questions…

Expert Care in Portland

Access hematopoietic and lymphatic system neoplasm specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hematopoietic and lymphatic system neoplasm treatment provided free

Apply for This Portland Location

Check if you qualify for this hematopoietic and lymphatic system neoplasm clinical trial in Portland, OR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Portland

    Convenient for OR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Portland site if eligible
  4. 4Begin participation

About This Hematopoietic and Lymphatic System Neoplasm Study in Portland

This phase II trial tests how well cytarabine (Ara-C), methotrexate, and hydrocortisone given between the spinal cord and the membranes that protect it (intrathecal \[IT\]) works in preventing high-grade immune effector-associated neurotoxicity syndrome (ICANS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy. ICANS is a challenging complication of CAR T-cell therapy that causes neurological effects varying from mild headaches or temporary confusion to hallucinations, swelling in the brain, and seizures. Between 20%-70% of patients receiving CAR T-cell therapy show symptoms of neurotoxicity.

Sponsor: OHSU Knight Cancer Institute

Who Can Participate

Inclusion Criteria

Written informed consent. Participant or legally authorized representative (LAR) must provide written informed consent prior to any study-specific procedures or interventions
Age ≥ 18 years. All genders, races, and ethnic groups will be included
Must be receiving SOC Yescarta® or Tecartus® in the inpatient setting
Agree to adhere to institutional guidelines for contraception during the first 30 days post CAR-T
Rationale for eligibility criteria based on contraception and pregnancy (both participants and partners of a sperm-producing participant): It shall be known to all participants that the effects of CAR-T or IT chemotherapy on the developing human fetus are unknown. For this reason, persons of reproductive potential must agree to use adequate contraception. Should a participant or participant's sexual partner become pregnant or suspect a pregnancy while participating in this study, the individual should inform their treating physician immediately
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Platelet count \> 50,000/mm\^3 (μL)
Adequate coagulation tests including international normalized ratio (INR) \< 1.6 and fibrinogen \> 100

Exclusion Criteria

Active/concurrent diagnosis of any central nervous system (CNS) hematologic malignancy
History or presence of CNS disorder such as poorly controlled seizure disorder (seizure within the 12 months), transverse myelitis, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement
Known history of hypersensitivity to IT chemotherapy
Subject has a contraindication to LP including:
Presence of a posterior fossa mass
Skin infection near puncture site
Uncorrected bleeding diathesis
Suspicion of increased intracranial pressure
Acute spinal cord trauma
Subject is receiving an antiplatelet and/or anticoagulant that cannot be held prior to LP according to best available evidence
Known bleeding disorders
Any other significant medical illness, abnormality, or condition that would, in the Investigator's judgement, make the participant inappropriate for study participation or would put the participant at risk

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Portland?

Yes, this clinical trial (NCT06895473) has an active research site in Portland, OR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hematopoietic and Lymphatic System Neoplasm Treatment Options in Portland, OR

If you're searching for hematopoietic and lymphatic system neoplasm treatment options in Portland, OR, this clinical trial (NCT06895473) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Portland research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced hematopoietic and lymphatic system neoplasm specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hematopoietic and lymphatic system neoplasm clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Portland, OR

See all essential tremor clinical trials recruiting in Portland — not just this study.

Browse Essential Tremor Trials in Portland →

Browse More Trials by Condition

Essential Tremor TrialsAnkylosing Spondylitis TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Portland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Portland, OR